Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GreenLight Biosciences Holdings (GRNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0700+0.0200 (+1.90%)
At close: 04:00PM EST
1.0400 -0.03 (-2.80%)
After hours: 05:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.0500
Open1.0500
Bid1.0400 x 800
Ask1.1100 x 800
Day's Range1.0400 - 1.0900
52 Week Range1.0000 - 15.8000
Volume117,676
Avg. Volume356,486
Market Cap162.161M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-18.4990
Earnings DateNov 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GRNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GreenLight Biosciences Holdings
    Daily – Vickers Top Insider Picks for 12/09/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

    GreenLight GreenLight’s mRNA design, formulation and manufacturing expertise is currently applied to research and develop mRNA vaccine candidates The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine designEpivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and differentiating highly immunogenic neo-antigens from epitopes that induce immune tole

  • GlobeNewswire

    GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

    GreenLight Biosciences lab GreenLight Biosciences lab Working toward clinical trial initiation for COVID vaccine candidate in 2023Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of IndiaCalantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approvalHoneybee solution EPA submission planned for 2023Strategic realignment focused on near-term value drivers. BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- GreenLight Bi

  • GlobeNewswire

    GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

    Credit Suisse annual conference GreenLight CEO Andrey Zarur will present to the Credit Suisse 31st Annual Healthcare Conference BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November. Cred

Advertisement
Advertisement